According to Future Market Insights' most recent industry report, the global Cell Therapy Manufacturing Market was valued at over US$ 3.3 billion in 2021 and is expected to grow at a CAGR of close to 14.2% during the forecast period. The market is estimated to reach US$ 13.9 billion by 2032.
Cell therapies are utilized widely to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. The introduction of reagents and closed-system automated equipment for the manufacturing of cellular therapies is an outcome of the increasing research activities in the field of such therapies.
Get Complete Access @ https://www.futuremarketinsights.com/reports/cell-therapy-manufacturing-market
A decentralized manufacturing model for clinical trials in cell therapies engaging multiple sites are being favored across the globe. Such instances advocate the treatment of patients using cells, which are produced by utilizing automated equipment at each participating center by considering a single, centrally held investigational new drug application (IND).
Many academic centers are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi-center clinical trials. The global cell therapy manufacturing market would thus observe a boom in the next decade. Besides, the introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approaches would further propel the overall growth in the market during the projected period.
Key Takeaways from Market Study
- By source, the autologous segment held a global market share of about 56.0% in 2021.
- Based on indication, the cancer segment held nearly 31.0% in 2021 in the cell therapy manufacturing market.
- In terms of purpose, the clinical segment accounted for around 42.0% of the global market share in 2021.
- Injectable route of administration of cell therapies generated a global market share of around 44.0% in 2021.
- By cell type, the hematopoietic stem cells (HSC) segment held a share of around 25.0% in the global cell therapy manufacturing market in 2021.
- By end use, the hospital settings category generated a share of around 38.1% in 2021 in the global cell therapy manufacturing market.
- China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.
Competitive Landscape: Cell Therapy Manufacturing Market
Key players in the cell therapy manufacturing market are focusing on RD activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify the transition from clinical development to commercial manufacturing among cell therapy developers.
- Charles River Laboratories' Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Get Exclusive Insights on Cell Therapy Manufacturing Market
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
